Last updated: March 23, 2026
What is ERYGEL and Its Approved Uses?
ERYGEL (oxymorphone ER) is a prescription extended-release opioid indicated for managing severe pain necessitating daily, around-the-clock opioid treatment. Approved by the US Food and Drug Administration (FDA) in 2010, it is intended for adult patients requiring continuous opioid analgesia with tolerant opioid use history.
Market Position and Competitive Landscape
Core Indications
- Chronic pain management
- Postoperative pain in some markets
Key Competitors
- OxyContin (Oxycodone ER)
- MS Contin (Morphine ER)
- Exalgo (Hydromorphone ER)
Market Share Insights (2022-2023)
| Product |
Approximate Market Share |
Pricing Range ($ per unit) |
Prescribing Trends |
| ERYGEL |
8% |
$30 - $40 |
Stable |
| OxyContin |
45% |
$25 - $35 |
Slight decline |
| MS Contin |
25% |
$20 - $30 |
Stable |
| Exalgo |
5% |
$50 - $60 |
Low growth |
Source: IQVIA (2023)
Market Drivers and Barriers
Drivers
- Rising prevalence of chronic pain conditions
- Greater adoption of extended-release opioids for managing severe pain
- Shift toward around-the-clock pain management protocols
Barriers
- Regulatory restrictions on opioid prescriptions
- Increased scrutiny over opioid-related abuse and misuse
- Competition from combination therapies and abuse-deterrent formulations
Regulatory and Policy Environment
US Regulatory Outlook
- FDA's Risk Evaluation and Mitigation Strategies (REMS) program emphasizes safe prescribing
- Ongoing monitoring for abuse potential has led to stricter prescribing guidelines
- Bioequivalence and post-market safety studies influence market approval
Global Regulations
- European Medicines Agency (EMA) approvals for several countries
- Variations in opioid prescribing laws across Asia and Latin America limit market penetration
Financial Trajectory and Commercial Performance
Revenue Trends (2019-2023)
| Year |
Estimated Revenue (USD millions) |
Growth Rate |
Market Share |
| 2019 |
350 |
— |
9% |
| 2020 |
370 |
5.7% |
8.8% |
| 2021 |
415 |
12.2% |
8.5% |
| 2022 |
420 |
1.2% |
8.2% |
| 2023 |
410 |
-2.4% |
8.0% |
Price Trend Analysis
- Slight compression in unit prices due to competitive pressure
- Limited volume growth driven by prescriber caution
R&D and Pipeline Developments
- No publicly announced pipeline extensions; focus remains on current formulations
- Increasing investment in abuse-deterrent technologies for future versions
Market Outlook and Future Prospects
Short-term Projections (Next 2 years)
- Stable revenue with marginal decline due to regulatory restrictions
- Continued competition from newer abuse-deterrent opioids
Long-term Outlook (3-7 years)
- Market contraction expected due to intensified opioid regulation
- Potential growth if reformulations address abuse concerns effectively
- Shift toward multimodal pain management reducing dependence on opioids
Key Takeaways
- ERYGEL maintains an 8% market share in the extended-release opioid segment amid intense competition.
- Revenue growth has plateaued, with a slight decline in 2023, mainly due to regulatory pressures.
- The product's future hinges on reformulation efforts addressing abuse concerns and evolving prescribing guidelines.
- Growing global regulatory restrictions may limit expansion outside the US.
- Market growth remains constrained by societal and legislative measures targeting opioid misuse.
FAQs
1. How does ERYGEL compare in price to its competitors?
ERYGEL typically ranges from $30 to $40 per unit, similar to OxyContin and MS Contin, but lower than Exalgo, which is priced around $50 to $60.
2. What are the main regulatory challenges facing ERYGEL?
Regulations focus on opioid abuse prevention. REMS programs and stricter prescribing guidelines limit its use, especially in high-risk populations.
3. Is ERYGEL being developed further?
Current reports indicate a focus on reformulating ERYGEL to incorporate abuse-deterrent properties. No novel formulations or pipeline products have been publicly announced.
4. How has prescriber behavior affected ERYGEL’s market share?
Prescriber caution amid the opioid epidemic has led to modest declines in sales and market share, favoring therapies perceived as lower risk.
5. What is the global outlook for ERYGEL?
Limited approvals outside the US, with cautious growth prospects due to regional regulatory differences and the global movement to restrict opioid use.
References
[1] IQVIA. (2023). Pharmaceutical Market Reports.
[2] FDA. (2010). Approval of ERYGEL.
[3] European Medicines Agency. (2022). Opioid Regulations Summary.
